Scimago Lab
powered by Scopus
eISSN: 1941-5923
call: +1.631.629.4328
Mon-Fri 10 am - 2 pm EST


Medical Science Monitor Basic Research


Fluctuation of Hepatic Focal Nodular Hyperplasia Size with Oral Contraceptives Use

Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Unexpected drug reaction , Rare disease, Clinical situation which can not be reproduced for ethical reasons

Susumu Fukahori, Tetsuya Kawano, Yasushi Obase, Yasuhiro Umeyama, Nanae Sugasaki, Akitoshi Kinoshita, Chizu Fukushima, Masaki Yamakawa, Katsuhisa Omagari, Hiroshi Mukae

Japan Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Nagasaki, Japan

Am J Case Rep 2019; 20:1124-1127

DOI: 10.12659/AJCR.916398

Available online: 2019-07-30

Published: 2019-07-30


BACKGROUND: Focal nodular hyperplasia (FNH) of the liver is a rare benign nodular lesion that arises in women of reproductive age. Although a role of female hormones has been suggested, their influence on the course of FNH has remained controversial.
CASE REPORT: A 44-year-old woman with a 12-year history of oral contraceptive use was referred to our hospital for examination of an asymptomatic liver mass (3 cm in diameter) identified by computed tomography. We diagnosed FNH using imaging methods and fine-needle biopsy. Oral contraceptives were discontinued because the mass increased over a period of 21 months. Four months later, the mass had decreased in size, indicating that FNH can spontaneously regress when oral contraceptives are discontinued.
CONCLUSIONS: Discontinuation of oral contraceptives use can reduce the size of FNH, as in this case.

Keywords: Contraceptives, Oral, Hormonal, Focal nodular hyperplasia, Gonadal Steroid Hormones